DNA-binding agents.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Cancer chemotherapy and biological response modifiers

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0921-4410(03)21008-5PMID 12703206
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase II study of Temozolomide in advanced untreated pancreatic cancer

  2004cited by this paper
• A Phase II Trial of Temozolomide for Patients with Recurrent or Progressive Brain Metastases

  2004cited by this paper
• A Phase I Trial of the Oral Platinum Analogue JM216 with Concomitant Radiotherapy in Advanced Malignancies of the Chest

  2004cited by this paper
• Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation

  2004cited by this paper
• Cyclophosphamide, cisplatin, and carmustine: pharmacokinetics of carmustine following multiple alkylating-agent interactions

  2004cited by this paper
• Neoadjuvant Gemcitabine/treosulfan Chemotherapy for Newly Diagnosed Glioblastoma

  2004cited by this paper
• Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination.

  2003cited by this paper
• Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.

  2003cited by this paper
• Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?

  2003cited by this paper
• Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

  2003cited by this paper
• O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme.

  2003cited by this paper
• Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial.

  2003cited by this paper
• Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.

  2003cited by this paper
• Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

  2003cited by this paper
• Induction Chemotherapy With Gemcitabine and Oxaliplatin for Locally Advanced Cervical Carcinoma

  2003cited by this paper
• Gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the urothelium: a pilot study.

  2003cited by this paper
• Phase II trial of temozolomide in patients with progressive low-grade glioma.

  2003cited by this paper
• Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.

  2003cited by this paper
• Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.

  2003cited by this paper
• Results of the Randomized International Adjuvant Lung Cancer Trial (IALT): Cisplatin-based chemotherapy (CT) vs no CT in 1867 patients (pts) with resected non-small cell lung cancer (NSCLC)

  2003cited by this paper
• Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

  2003cited by this paper
• Telomere dysfunction increases cisplatin and ecteinascidin-743 sensitivity of melanoma cells.

  2003cited by this paper
• Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase.

  2003cited by this paper
• A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer.

  2003cited by this paper
• 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials.

  2003cited by this paper
• Ultrasound screening for the early detection of ovarian cancer.

  2003cited by this paper
• Oxaliplatin plus raltitrexed in the treatment of patients with advanced colorectal cancer: a phase II study.

  2003cited by this paper
• Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice.

  2003cited by this paper
• Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.

  2003cited by this paper
• Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma

  2003cited by this paper
• Oxaliplatin for colorectal cancer in the United States: better late than never.

  2003cited by this paper
• Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965).

  2003cited by this paper
• A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.

  2003cited by this paper
• Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial

  2003cited by this paper
• High dose chemotherapy and stem cell support in the treatment of germ cell cancer.

  2003cited by this paper
• Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer.

  2003cited by this paper
• Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials.

  2003cited by this paper
• Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer.

  2003cited by this paper
• Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas.

  2003cited by this paper
• Phase II study of the efficacy and safety of cisplatin-epinephrine injectable gel administered to patients with unresectable hepatocellular carcinoma.

  2003cited by this paper
• Temozolomide in combination with interferon α‐2b in patients with metastatic melanoma

  2003cited by this paper
• Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

  2003cited by this paper
• An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.

  2003cited by this paper
• Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.

  2003cited by this paper
• Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors

  2003cited by this paper
• Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study.

  2003cited by this paper
• Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation.

  2003cited by this paper
• Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.

  2003cited by this paper
• HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen.

  2003cited by this paper
• Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504.

  2003cited by this paper
• Current status of oxaliplatin in colorectal cancer.

  2003cited by this paper
• Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival.

  2003cited by this paper
• A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.

  2003cited by this paper
• Current role and future perspectives for ifosfamide in the treatment of malignant non-Hodgkin's lymphoma--results from an expert meeting.

  2003cited by this paper
• Phase I–II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer

  2003cited by this paper
• Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma

  2003cited by this paper
• Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNα in patients with metastatic melanoma

  2003cited by this paper
• Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study

  2003cited by this paper
• High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

  2003cited by this paper
• Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.

  2003cited by this paper
• Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431.

  2002cited by this paper
• Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

  2002cited by this paper
• CISPLATIN INDUCES ACUTE RENAL FAILURE BY IMPAIRING ANTIOXIDANT SYSTEM IN GUINEA PIGS: EFFECTS OF ANTIOXIDANT SUPPLEMENTATION ON THE CISPLATIN NEPHROTOXICITY

  2002cited by this paper
• Treosulfan in the treatment of advanced ovarian cancer: a randomised co-operative multicentre phase III-study.

  2002cited by this paper
• Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial.

  2002cited by this paper
• Long-term follow-up of patients treated with paclitaxel/carboplatin-based chemotherapy for advanced non-small-cell lung cancer: sequential phase II trials of the Minnie Pearl Cancer Research Network.

  2002cited by this paper
• Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer.

  2002cited by this paper
• Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD).

  2002cited by this paper
• Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix.

  2002cited by this paper
• Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.

  2002cited by this paper
• Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma.

  2002cited by this paper
• Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning.

  2002cited by this paper
• Preclinical and phase I study of oxaliplatin and topotecan in combination in human cancer.

  2002cited by this paper
• Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity

  2002cited by this paper
• Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study

  2002cited by this paper
• Long-term renal function after treatment for malignant germ-cell tumours.

  2002cited by this paper
• Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients

  2002cited by this paper
• Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial.

  2002cited by this paper
• Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas.

  2002cited by this paper
• Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma.

  2002cited by this paper
• Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin.

  2002cited by this paper
• A phase II trial of JM-216 in cervical cancer: an NCIC CTG study.

  2002cited by this paper
• Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study.

  2002cited by this paper
• Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis

  2002cited by this paper
• Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.

  2002cited by this paper
• High-dose carboplatin and regimen-related toxicity following autologous bone marrow transplant

  2002cited by this paper
• Inhibition of glutathione S‐transferases by antimalarial drugs possible implications for circumventing anticancer drug resistance

  2002cited by this paper
• Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck.

  2002cited by this paper
• Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer.

  2002cited by this paper
• Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases.

  2002cited by this paper
• Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.

  2002cited by this paper
• Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients.

  2002cited by this paper
• Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma

  2002cited by this paper
• Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.

  2002cited by this paper
• Late complications following treatment for severe aplastic anemia (SAA) with high-dose cyclophosphamide (Cy): follow-up of a randomized trial.

  2002cited by this paper
• Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs.

  2002cited by this paper
• The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation.

  2002cited by this paper
• Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.

  2002cited by this paper
• Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019.

  2002cited by this paper
• A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.

  2002cited by this paper

• Synergistic Effect of Yeast and Cisplatin against Induced Skeletal Muscle Carcinoma in Mice: Histological Study

  2020cites this paper
• Synthesis and cellular effects of novel 1,3,5-triazine derivatives in DLD and Ht-29 human colon cancer cell lines

  2019cites this paper
• Study of Nucleic Acid Binding of Aloe emodin and Emodin by Spectroscopic Techniques

  2018cites this paper
• High Mobility Group B Proteins, Their Partners, and Other Redox Sensors in Ovarian and Prostate Cancer

  2015cites this paper
• Synthesis and DNA binding profile of N-mono- and N,N'-disubstituted indolo[3,2-b]carbazoles.

  2015cites this paper
• Design, modeling, synthesis and biological activity evaluation of camptothecin-linked platinum anticancer agents.

  2013cites this paper
• Natural product DNA major groove binders.

  2012cites this paper
• Synthesis and cytotoxicity studies of bifunctional hybrids of nitrogen mustards with potential enzymes inhibitors based on melamine framework

  2012cites this paper
• Application of comet assay for the assessment of DNA damage caused by chemical genotoxins in the dairy yeast Kluyveromyces lactis

  2012cites this paper
• Binding of cationic dyes to DNA: distinguishing intercalation and groove binding mechanisms using simple experimental and numerical models

  2010cites this paper
• New insights in the DNA-[Cr(phen)2(dppz)]3+ binding and photocleavage properties by the complex with an intercalating ligand.

  2010cites this paper
• Pharmacological profile and clinical features of cisplatin

  2009cites this paper
• The prognostic role of matrix metalloproteinases MMP-2 and -9 and their tissue inhibitors TIMP-1 and -2 in primary breast carcinoma

  2007cites this paper
• BENA435, a new cell-permeant photoactivated green fluorescent DNA probe

  2006cites this paper
• Cell-based assays for profiling activity and safety properties of cancer drugs.

  2006cites this paper
• Synthese und Charakterisierung DNA-bindender Peptide

  2006influential citation
• The search of DNA-intercalators as antitumoral drugs: what it worked and what did not work.

  2005cites this paper
• Antagonism of HSV-tk Transfection and Ganciclovir Treatment on Chemotherapeutic Drug Sensitivity

  2005cites this paper
• Binding of a homologous series of anthraquinones to DNA.

  2004cites this paper
• Sequence-selective DNA recognition: natural products and nature's lessons.

  2004cites this paper
• Molecular and crystal structure of 5-amino-1H-[1,2,4]triazole-3-carboxylic acid derivatives

  2003cites this paper
• CONCEPTION, SYNTHESE ET EVALUATION PHARMACOLOGIQUE DE PYRROLO(3,4-b)QUINOLEINES CONDENSEES, LIGANDS POTENTIELS DE L'ADN

  2003cites this paper